Journal ArticleDOI
Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes.
Hyun Ju Lee,Young Tae Kim,Chang Hyun Kang,Binsheng Zhao,Yongqiang Tan,Lawrence H. Schwartz,Thorsten Persigehl,Thorsten Persigehl,Thorsten Persigehl,Yoon Kyung Jeon,Doo Hyun Chung +10 more
TLDR
GGO volume percentage in tumors with exon 21 missense mutation was significantly higher than that in tumor status with other EGFR mutation status, and can be related to the fact that exon21 missense mutations was significantly more frequent in lepidic predominant adenocarcinomas, according to IASLE/ATS/ERS classification.Abstract:
Ground-glass opacity volume percentage in tumors with exon 21 missense mutation was significantly higher than that in epidermal growth factor receptor wild-type tumors and exon 19–mutated tumors.read more
Citations
More filters
Journal ArticleDOI
Intrinsic dependencies of CT radiomic features on voxel size and number of gray levels.
Muhammad Shafiq-ul-Hassan,Geoffrey Zhang,Kujtim Latifi,Ghanim Ullah,Dylan C. Hunt,Yoganand Balagurunathan,Mahmoud A. Abdalah,Matthew B. Schabath,Dmitry G. Goldgof,Dennis Stephen Mackin,Laurence E. Court,Robert J. Gillies,Eduardo G. Moros +12 more
TL;DR: The impact of slice thickness and pixel spacing on radiomics features extracted from Computed Tomography (CT) phantom images acquired with different scanners as well as different acquisition and reconstruction parameters was investigated.
Journal ArticleDOI
Reproducibility of radiomics for deciphering tumor phenotype with imaging.
TL;DR: Assessment of the reproducibility of a comprehensive, commonly-used set of radiomic features using a unique, same-day repeat computed tomography data set from lung cancer patients suggests that radiomic Features are reproducible over a wide range of imaging settings.
Journal ArticleDOI
Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas.
Ying Liu,Jongphil Kim,Yoganand Balagurunathan,Qian Li,Alberto Garcia,Olya Stringfield,Zhaoxiang Ye,Robert J. Gillies +7 more
TL;DR: Computed tomography-based radiomic features of peripheral lung adenocarcinomas can capture useful information regarding tumor phenotype, and the model built can be useful to predict the presence of EGFR mutations in peripheral lung carcinomas in Asian patients when mutational profiling is not available or possible.
Journal ArticleDOI
CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer
Stefania Rizzo,Francesco Petrella,Valentina Buscarino,Federica De Maria,Sara Raimondi,Massimo Barberis,Caterina Fumagalli,Gianluca Spitaleri,Cristiano Rampinelli,Filippo de Marinis,Lorenzo Spaggiari,Massimo Bellomi,Massimo Bellomi +12 more
TL;DR: Air bronchogram, pleural retraction, small size relate to EGFR mutation in NSCLC, and ALK rearrangements were associated with age and pleural effusion, and KRAS mutation was associated with round shape, nodules in non-tumour lobes, and smoking.
Journal ArticleDOI
Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.
Hugo J.W.L. Aerts,Patrick Grossmann,Yongqiang Tan,Geoffrey R. Oxnard,Naiyer A. Rizvi,Lawrence H. Schwartz,Binsheng Zhao +6 more
TL;DR: This pilot study shows that radiomic data before treatment is able to predict mutation status and associated gefitinib response non-invasively, demonstrating the potential of radiomics-based phenotyping to improve the stratification and response assessment between tyrosine kinase inhibitors (TKIs) sensitive and resistant patient populations.
References
More filters
Journal ArticleDOI
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
TL;DR: Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.
Journal ArticleDOI
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
TL;DR: Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
Journal ArticleDOI
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo,Akira Inoue,Kunihiko Kobayashi,Shunichi Sugawara,Satoshi Oizumi,Hiroshi Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,Haruto Hirano,Kozo Yoshimori,Toshiyuki Harada,Takashi Ogura,Masahiro Ando,Hitoshi Miyazawa,Tomoaki Tanaka,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +22 more
TL;DR: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Journal ArticleDOI
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis,Elisabeth Brambilla,Masayuki Noguchi,Andrew G. Nicholson,Kim R. Geisinger,Yasushi Yatabe,David G. Beer,Charles A. Powell,Gregory J. Riely,Paul Van Schil,Kavita Garg,John H. M. Austin,Hisao Asamura,Valerie W. Rusch,Fred R. Hirsch,Giorgio V. Scagliotti,Tetsuya Mitsudomi,Rudolf M. Huber,Yuichi Ishikawa,James R. Jett,Montserrat Sanchez-Cespedes,Jean-Paul Sculier,Takashi Takahashi,Masahiro Tsuboi,Johan Vansteenkiste,Ignacio I. Wistuba,Pan-Chyr Yang,Denise R. Aberle,Christian Brambilla,Douglas B. Flieder,Wilbur A. Franklin,Adi F. Gazdar,Michael K. Gould,Philip S. Hasleton,Douglas W. Henderson,Bruce E. Johnson,David A Johnson,Keith M. Kerr,Keiko Kuriyama,Jin Soo Lee,Vincent A. Miller,Iver Petersen,Victor L. Roggli,Rafael Rosell,Nagahiro Saijo,Erik Thunnissen,M. Tsao,David Yankelewitz +47 more
TL;DR: This new adenocarcinoma classification is needed to provide uniform terminology and diagnostic criteria, especially for bronchioloalveolar carcinoma (BAC), the overall approach to small nonresection cancer specimens, and for multidisciplinary strategic management of tissue for molecular and immunohistochemical studies.
Related Papers (5)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis,Elisabeth Brambilla,Masayuki Noguchi,Andrew G. Nicholson,Kim R. Geisinger,Yasushi Yatabe,David G. Beer,Charles A. Powell,Gregory J. Riely,Paul Van Schil,Kavita Garg,John H. M. Austin,Hisao Asamura,Valerie W. Rusch,Fred R. Hirsch,Giorgio V. Scagliotti,Tetsuya Mitsudomi,Rudolf M. Huber,Yuichi Ishikawa,James R. Jett,Montserrat Sanchez-Cespedes,Jean-Paul Sculier,Takashi Takahashi,Masahiro Tsuboi,Johan Vansteenkiste,Ignacio I. Wistuba,Pan-Chyr Yang,Denise R. Aberle,Christian Brambilla,Douglas B. Flieder,Wilbur A. Franklin,Adi F. Gazdar,Michael K. Gould,Philip S. Hasleton,Douglas W. Henderson,Bruce E. Johnson,David A Johnson,Keith M. Kerr,Keiko Kuriyama,Jin Soo Lee,Vincent A. Miller,Iver Petersen,Victor L. Roggli,Rafael Rosell,Nagahiro Saijo,Erik Thunnissen,M. Tsao,David Yankelewitz +47 more
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Hugo J.W.L. Aerts,Emmanuel Rios Velazquez,Ralph T.H. Leijenaar,Chintan Parmar,Patrick Grossmann,Sara Carvalho,Sara Cavalho,Johan Bussink,René Monshouwer,Benjamin Haibe-Kains,Derek H. F. Rietveld,Frank J. P. Hoebers,Michelle M. Rietbergen,C. René Leemans,Andre Dekker,John Quackenbush,Robert J. Gillies,Philippe Lambin +17 more